Contaminated cough syrup no longer available in Africa, says WHO

22 April 2024 - 12:01 By Jennifer Rigby
subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now
The recalled batch of Benylin syrup was made by Johnson & Johnson in South Africa. Stock photo.
The recalled batch of Benylin syrup was made by Johnson & Johnson in South Africa. Stock photo.
Image: 123rf

A contaminated batch of Benylin paediatric syrup is no longer available in African countries where it was sold, the World Health Organisation (WHO) said on Monday.

Earlier this month, Nigeria recalled a batch of the children's cough and allergy medicine after tests found it contained unacceptable levels of the toxin diethylene glycol.

Five other African countries — Kenya, Rwanda, Tanzania, Zimbabwe and South Africa —have also pulled the product from shelves where the drug was made.

The recalled batch of Benylin syrup was made by Johnson & Johnson (J&J) in South Africa in May 2021, though Kenvue owns the brand after a spin-off from J&J last year.

J&J has referred requests for comment to Kenvue. In an e-mailed statement on Friday, Kenvue said it had carried out tests on the batch recalled by Nigeria and had not detected either diethylene or ethylene glycol, but was continuing to work with the authorities.

Diethylene glycol can cause acute kidney failure and alongside another related toxin, ethylene glycol, has been linked to the deaths of more than 300 children in Cameroon, Gambia, Indonesia and Uzbekistan since 2022 after being found in medicines made in India and Indonesia.

No children have been reported hurt or killed in the latest incident.

The WHO, which has warned countries and companies to be vigilant about the ongoing risk of contamination, said on Friday it was "likely" to issue a broader alert about Benylin. However, on Monday the health agency said it no longer had immediate plans to do so after receiving more information at the end of the week.

A spokesperson said: "Considering this batch is no longer on the market in any of the impacted countries and it has been consumed with no apparent reports of adverse effects, we believe there is no immediate public health risk."

Reuters


subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.